Evidence map›Paper›PMID 38544800›Full record

ArticleFrontiers in genetics2024

TCRpred: incorporating T-cell receptor repertoire for clinical outcome prediction.

Meiling Liu, Yang Liu, Li Hsu, Qianchuan He

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Meiling LiuPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Yang LiuDepartment of Mathematics and Statistics, Wright State University, Dayton, OH, United States.
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Qianchuan HePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Fred Hutch Cancer Center · USWright State University · US

Funding

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating UnitU24CA288185 · NCI · FRED HUTCHINSON CANCER CENTER · PI Wei Sun, Yingye Zheng · 2023 to 2026
$3.1M
Methods for Analyzing Cancer Somatic Mutation DataR01CA223498 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HE, QIANCHUAN · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA223498NCI NIH HHS U24 CA288185
6 · The paper itself

Abstract

T-cell receptor (TCR) plays critical roles in recognizing antigen peptides and mediating adaptive immune response against disease. High-throughput technologies have enabled the sequencing of TCR repertoire at the single nucleotide level, allowing researchers to characterize TCR sequences with high resolutions. The TCR sequences provide important information about patients' adaptive immune system, and have the potential to improve clinical outcome prediction. However, it is challenging to incorporate the TCR repertoire data for prediction, because the data is unstructured, highly complex, and TCR sequences vary widely in their compositions and abundances across different individuals. We introduce TCRpred, an analytic tool for incorporating TCR repertoire for clinical outcome prediction. The TCRpred is able to utilize features that can be extracted from the TCR amino acid sequences, as well as features that are hidden in the TCR amino acid sequences and are hard to extract. Simulation studies show that the proposed approach has a good performance in predicting clinical outcome and tends to be more powerful than potential alternative approaches. We apply the TCRpred to real cancer datasets and demonstrate its practical utility in clinical outcome prediction.

Indexed as

CDR3clinical outcome predictionhigh dimensionshigh throughput sequencingT-cell receptorTCR repertoire

Identifiers

PMID38544800
PMCPMC10965803
OpenAlexW4392754636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.